EUVIMEDOpdag EUVIMED
Crossref

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study

Saqr Alsakarneh iD, Omar Al Ta'ani iD, Razan Aburumman, Inas Mikhail, Jana G Hashash, Francis A Farraye

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70139 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Saqr Alsakarneh and 5 co-authors. Institution: Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA. Major MEDLINE topics: Arthritis, Psoriatic, Interleukin-17, Inflammatory Bowel Diseases, Psoriasis. Cited 21 times so far (Crossref); 10 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

IL‐17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL‐17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL‐17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL‐17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.

Subjects

MeSH terms (MEDLINE)

Arthritis, PsoriaticInterleukin-17Inflammatory Bowel DiseasesPsoriasisThalidomideAnti-Inflammatory Agents, Non-SteroidalHumansFemaleMaleMiddle AgedAdultRisk FactorsAgedAntibodies, Monoclonal, Humanized

Author keywords

IL‐17 inhibitorsSecukinumabinflammatory bowel disease

Substances

Interleukin-17apremilastThalidomideAnti-Inflammatory Agents, Non-SteroidalIL17A protein, humanAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID profiles: Saqr Alsakarneh, Omar Al Ta'ani

Cite

APA

Alsakarneh, S., Al Ta'ani, O., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70139

Vancouver

Alsakarneh S, Al Ta'ani O, Aburumman R, Mikhail I, Hashash JG, Farraye FA. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70139

BibTeX
@article{Alsakarneh2025,
  author = {Alsakarneh, Saqr and Al Ta'ani, Omar and Aburumman, Razan and Mikhail, Inas and Hashash, Jana G and Farraye, Francis A},
  title = {Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70139}
}
Start for free →